Treating non-small cell lung cancer (NSCLC) after it becomes resistant to chemotherapy has been the subject of intense scientific and clinical research. The study of targeted therapy, in which a drug or biological agent attaches only to a specific receptor on a malignant cell, led to the approval and release of the anilinoquinazolines gefitinib (Iressa) and erlotinib (Tarceva), for the treatment of patients with NSCLC who have failed or can ...
Read more...







Past 6 Months
Dear lawmakers: This is what it’s like to be a doctor today
Matthew Moeller, MD | PhysicianA gun owner responds to Sandy Hook
Edwin Leap, MD | PhysicianIs Chris Christie too obese to run for president?
Jeffrey Parks, MD | PhysicianIf I’m wrong about guns, can you please explain why?
Claire McCarthy, MD | PhysicianPrimary care doctors may no longer be needed
Doug Olson, MD | PhysicianWalgreens moves into primary care, and it’s our own damn fault
Kevin Pho, MD | Kevin's Take